Abstract
Identification of rare genetic variants associated with schizophrenia has proven challenging due to multiple sources of heterogeneity, which may be reduced in founder populations. We examined ultra-rare exonic variants in 786 patients with schizophrenia and 463 healthy comparison subjects, all drawn from the Ashkenazi Jewish population. Cases had a higher frequency of novel missense or loss of function (MisLoF) variants compared to controls. Characterizing 141 “case-only” genes (in which ≥ 3 cases in our dataset had MisLoF variants with none found in controls), we identified cadherins as a novel gene set associated with schizophrenia, including a recurrent mutation in PCDHA3. Modeling the effects of purifying selection demonstrated that deleterious ultra-rare variants are greatly over-represented in the Ashkenazi population, resulting in enhanced power for rare variant association. Identification of cell adhesion genes in the cadherin/protocadherin family helps specify the synaptic abnormalities central to the disorder and suggests novel potential treatment strategies.
Introduction
Schizophrenia is a highly heritable neurodevelopmental disorder, yet common genetic variants identified through large-scale Genome-Wide Association Studies (GWAS) account for only a fraction of its heritability. A significant portion of the remaining risk is believed to lie in rare variants. However, identifying these variants is complicated by locus heterogeneity and purifying selection, which keeps damaging mutations at extremely low frequencies.
This study by Lencz et al. addresses these challenges by focusing on the Ashkenazi Jewish (AJ) population. As a founder population that underwent a severe bottleneck followed by rapid expansion, the AJ population offers a unique genetic landscape where rare, deleterious mutations can reach higher frequencies than in more diverse populations. This "hitchhiking" effect provides increased statistical power to detect associations between ultra-rare variants (URVs) and complex diseases like schizophrenia.
Methods
The researchers performed Whole-Genome Sequencing (WGS) on 1,346 AJ individuals, including 786 patients with schizophrenia and 463 healthy controls. The analysis focused on the exome to identify "novel" variants—those absent from major public databases like gnomAD and TOPMed.
Variants were classified as "Missense or Loss of Function" (MisLoF) if they were predicted to significantly alter protein function. The study utilized a "case-only" analysis, identifying genes where at least three cases possessed a MisLoF mutation while none were found in controls. To validate the power of the AJ population, the team conducted 10,000 permutations to model the effects of purifying selection during population expansion. Additionally, common variant Polygenic Risk Scores (PRS) were integrated to explore the relationship between rare and common genetic risk factors.
Results
The analysis revealed a significant enrichment of novel exome-wide singletons in schizophrenia cases compared to controls ($p = 6.13 \times 10^{-10}$). Specifically, cases showed a higher degree of elevation for "case-only" genes hit by damaging URVs. This effect was particularly pronounced for MisLoF variants ($p=0.0001$), as visualized in Figure 1.
Beyond confirming known schizophrenia risk genes (e.g., SETD1A, TRIO), the study identified the cadherin protein class as a novel gene set significantly associated with the disorder ($p = 7.75 \times 10^{-6}$). Table 2 details the enrichment across various biological processes and protein families, highlighting the role of cell adhesion molecules.
A key finding was a recurrent missense variant in PCDHA3, found in five cases and zero controls. This variant has a high predicted damage score (CADD = 23.4) and is present in 0.3% of AJ cases, a remarkably high frequency for a schizophrenia-associated URV. Furthermore, the study provided evidence for a "liability threshold" model: patients with a high burden of rare damaging mutations tended to have lower polygenic risk from common variants, suggesting these rare mutations exert a substantial individual effect on disease risk.
Discussion
The findings underscore the power of founder populations in uncovering the genetic architecture of complex disorders. By identifying cadherins and protocadherins—proteins essential for synaptic "barcoding" and neuronal connectivity—the study points toward specific synaptic abnormalities in schizophrenia. While the sample size is modest compared to global consortia, the population-specific approach yielded high-impact results. Future research will focus on functional studies to elucidate how these specific mutations disrupt neural circuits, potentially opening doors to novel therapeutic interventions targeting cell-adhesion pathways.
Summary updated